Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

AI-powered tools helped Moderna and Merck develop a personalised mRNA cancer vaccine, with Elon Musk claiming that curing ...

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with ...

Keytruda plus personalized mRNA vaccine tops melanoma trial, lifts Moderna Personalized mRNA shot with Keytruda delays ...

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of recurrence and spread of skin cancer in a late- ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...

Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment.

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer ...